drugset / Trial / NCT00799656

Efficacy and Safety Study of Ataciguat Versus Placebo in Patients With Neuropathic Pain

NCT00799656

Phase 2 Completed 62 enrolled Sanofi
RandomizedCrossoverDouble-blindTreatment

Summary

The primary objective of this study is to assess the efficacy of ataciguat versus placebo in reducing pain intensity in patients with neuropathic pain. The secondary objective is to assess the safety and tolerability of ataciguat versus placebo.

Timeline

Start
2008-11
Primary completion
2009-06
Completion
2009-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Ataciguat Small molecule 200 mg Oral

Indications

No indication recorded.